Quarterly report [Sections 13 or 15(d)]

REVENUES (Tables)

v3.25.1
REVENUES (Tables)
3 Months Ended
Mar. 31, 2025
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

​

​

2025

    

2024

Product sales:

​

​

​

​

​

​

Gross product sales

​

$

60,192

​

$

38,426

Discounts and allowances

​

​

(16,642)

​

​

(12,423)

Total product sales, net

​

​

43,550

​

​

26,003

Revenues from collaborations:

​

​

​

​

​

​

Milestone revenue

​

​

3,000

​

​

—

Delivery of drug supplies, royalty and others

​

​

6,783

​

​

3,531

Total revenues from collaborations

​

​

9,783

​

​

3,531

Total revenues

​

$

53,333

​

$

29,534

Schedule of product revenue allowance and reserve categories

The following tables summarize the activities in chargebacks, discounts and fees, government and other rebates and returns that were accounted for within revenue reserves and refund liability, for each of the periods presented (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2025

    

$

13,374

​

$

8,343

​

$

4,723

​

$

26,440

Provision related to current period sales

​

​

12,811

​

​

3,654

​

​

398

​

​

16,863

Adjustment related to prior period sales

​

​

—

​

​

(148)

​

​

(560)

​

​

(708)

Credit or payments made during the period

​

​

(12,928)

​

​

(1,669)

​

​

(63)

​

​

(14,660)

Balance as of March 31, 2025

 

$

13,257

​

$

10,180

​

$

4,498

​

$

27,935

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2024

    

$

8,236

​

$

3,517

​

$

3,931

​

$

15,684

Provision related to current period sales

​

​

9,763

​

​

2,280

​

​

224

​

​

12,267

Credit or payments made during the period

​

​

(10,255)

​

​

(1,609)

​

​

(42)

​

​

(11,906)

Balance as of March 31, 2024

 

$

7,744

​

$

4,188

​

$

4,113

​

$

16,045

Schedule of revenues from product sales disaggregated by customers

​

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

​

​

2025

    

2024

McKesson Corporation

​

​

42%

​

​

42%

Cencora Inc. (formerly ASD Healthcare)

​

​

20%

​

​

23%

Optime Care, Inc.

​

​

11%

​

​

*

Cardinal Health, Inc.

​

​

*

​

​

23%